Daniel Schäfle
YOU?
Author Swipe
Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics Open
Peripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired in…
The aminoglycoside-modifying enzyme Eis2 represents a new potential<i>in vivo</i>target for reducing antimicrobial drug resistance in<i>Mycobacterium abscessus</i>complex Open
This study identified innovative therapeutic targets to reinforce existing current antibiotic treatments against M. abscessus complex, exploiting a murine preclinical model of respiratory infection and 727 publicly available genomes from c…
Drug Susceptibility Distributions of Mycobacterium chimaera and Other Nontuberculous Mycobacteria Open
Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections have highlighted the importance of species differentiation within the Mycobacterium avium complex and pointed to a lack of antibiotic susceptibility data for …
Rifabutin Is Inactivated by Mycobacterium abscessus Arr Open
Mycobacterium abscessus exhibits arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in M. abscessus infection models, implying that RBT might not be inactiv…
Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation Open
The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Among the…
Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics Open
Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a …
Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics Open
Fidaxomicin ( 1 , tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of Clostridium difficile infections. Based on the analysis of a cryo‐EM structure of fidaxomicin binding to its target enzyme (RNA‐polym…
Semisynthetic Analogs of the Antibiotic Fidaxomicin – Design, Synthesis, and Biological Evaluation Open
The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Main limi…
Semisynthetic Analogs of the Antibiotic Fidaxomicin – Design, Synthesis, and Biological Evaluation Open
The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Main limi…
Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics Open
Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a …
Novel Fidaxomicin Antibiotics through Site-Selective Catalysis Open
Fidaxomicin (FDX) is a marketed antibiotic for the treatment Clostridium difficile infections (CDI). Although showing interesting antibacterial properties against many Gram-positive bacteria, the application of this antibiotic is currently…
Novel Fidaxomicin Antibiotics through Site-Selective Catalysis Open
Fidaxomicin (FDX) is a marketed antibiotic for the treatment Clostridium difficile infections (CDI). Although showing interesting antibacterial properties against many Gram-positive bacteria, the application of this antibiotic is currently…
Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics Open
Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a …
KatG as Counterselection Marker for Nontuberculous Mycobacteria Open
In a recent issue of Antimicrobial Agents and Chemotherapy, Reingewertz et al. (1) report on sensitization of slow-growing, nontuberculous mycobacteria (NTM) to the anti-tubercular drug isoniazid (INH) upon expression of Mycobacterium bovi…